The clinical impact of f-fdg gamma pet in patients with recurrent well differentiated thyroid carcinoma

Nuclear Medicine Communications

Volumn 24, Issue 9, 2003, Pages 959-961

  Goshen, E ^a   Cohen, O ^a   Rotenberg, G ^a   Oksman, Y ^a   Karasik, A ^a   Zwas, S T ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

F FDG; Gamma PET; Thyroid carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; EVALUATION; FEMALE; FIBROSIS; GAMMA RADIATION; HUMAN; IMMOBILIZATION; LABORATORY DIAGNOSIS; MALE; MEDICAL DECISION MAKING; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RETROSPECTIVE STUDY; THYROID CARCINOMA; TUMOR DIFFERENTIATION; VALIDATION PROCESS; WHOLE BODY TOMOGRAPHY; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEAD AND NECK TUMOR; MEDIASTINUM TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; PAPILLARY CARCINOMA; SCINTILLATION CAMERA; SCINTISCANNING; THYROID TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE; WHOLE BODY COUNTING;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; FLUORODEOXYGLUCOSE F18; GAMMA CAMERAS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME; WHOLE-BODY COUNTING;

EID: 4444366490     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200309000-00003     Document Type: Article

References (10)

1. Gambhir S, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 15S-93S.
2. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose. J Nucl Med 1987; 28: 910-914.
3. Grunwald F, Kalicke T, Feine V, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26: 1547-1552.
4. Yeo JS, Chung JK, So Y, et al. F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 2001; 23: 94-103.
5. Frilling A, Gorges R, Tecklenborg K, et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000; 128: 1067-1074.
6. Frilling A, Tecklenborg K, Gorge R, Weber F, Clausen M, Broelsch EC. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001; 234: 804-811.
7. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001; 42: 1464-1469.
8. Jadvar H, McDougall IR, Segall GM. Evaluation of suspected recurrent papillary thyroid carcinoma with [(18)F] fluorodeoxyglucose positron emission tomography. Nucl Med Commun 1998; 19: 547-554.
9. Moog F, Linke R, Manthey N, et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000; 41: 1989-1995.
10. 131I-negative papillary thyroid carcinoma. J Nucl Med 2000; 41: 1010-1015.